gb GENETIC A1AT
Detection method:
allelic discrimination
This in vitro diagnostic kit is intended for detection of mutations PI*S and PI*Z in the alpha 1 antitrypsin gene in human genomic DNA. Detection is based on real-time polymerase chain reaction (qPCR) using fluorescently labelled probes (allelic discrimination).
Clinical implications of the CE IVD kit
Alpha-1-antitrypsin (A1AT) is one of the serine protease inhibitors (SERPIN) which serves as an inhibitor of neutrofile elastase in lungs. The mutations in the A1AT gene lead to changes in
the protein structure and loss of function. Alpha-1-antitrypsin deficiency is associated with lung diseases such as chronic obstructive pulmonary disease (COPD).
The main risk factors for COPD are smoking, dusty work or repeated respiratory infections. A1AT deficiency can cause liver disease (hepatitis, cirrhosis) in both, neonates and adults. The most frequent mutations which cause a deficiency in alpha-1-antitrypsin are PI*S and PI*Z. Mutation PI*S is caused by substitution of E264V and makes a gradual reduction in protein levels. Mutation PI*Z is caused by substitution of E342K and makes a significant A1AT level reduction in blood serum.
Parameters of the real-time PCR diagnostic kit
- ready-to-use assay
- sample concentration 1-100 ng/µl
- positive and negative controls included
- FAM and HEX channels detection
- identical amplification profile as gb HEMO, gb GENETIC, gb PHARM kits
Validated for:
ABI 7500/7500 Fast (ABI)
CFX96/96Touch (Bio-Rad)
Light Cycler 480/Cobas z480 (Roche Diagnostics)
MIC (BMS)
QuantStudio 5 (Applied Biosystems)
RG 3000 (Corbett Research)
RG 6000/Q (Corbett Research/Qiagen)